C. F. Pollera

976 total citations
14 papers, 542 citations indexed

About

C. F. Pollera is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, C. F. Pollera has authored 14 papers receiving a total of 542 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Surgery, 6 papers in Oncology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in C. F. Pollera's work include Bladder and Urothelial Cancer Treatments (6 papers), Cancer Research and Treatments (3 papers) and Urinary and Genital Oncology Studies (3 papers). C. F. Pollera is often cited by papers focused on Bladder and Urothelial Cancer Treatments (6 papers), Cancer Research and Treatments (3 papers) and Urinary and Genital Oncology Studies (3 papers). C. F. Pollera collaborates with scholars based in Italy. C. F. Pollera's co-authors include F. Calabresi, A. Ceribelli, M Crecco, Cesare Gridelli, M. De Lena, G Luporini, Mauro Antimi, Giovanni Luca Frassineti, Vito Lorusso and Michael Pacini and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

C. F. Pollera

14 papers receiving 526 citations

Peers

C. F. Pollera

SURGE

ONCOL

PRM

EPIDE

K. Jauhiainen Finland

Jennifer J. Findeis-Hosey United States

Jst Sham Hong Kong

Diana Lim Singapore

Slavko Gašparov Croatia

Jun Chul Chung South Korea

YH Park South Korea

Jasper J.H. Eijsink Netherlands

Yu Yu Andreeva Russia

Han Xiao United States

K. Jauhiainen Finland

C. F. Pollera

547 ×1.4

SURGE

227 ×1.3

ONCOL

127 ×0.9

PRM

97 ×1.1

EPIDE

151 ×2.8

Citations per year, relative to C. F. Pollera C. F. Pollera (= 1×) peers K. Jauhiainen

Countries citing papers authored by C. F. Pollera

Since Specialization

Citations

This map shows the geographic impact of C. F. Pollera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. F. Pollera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. F. Pollera more than expected).

Fields of papers citing papers by C. F. Pollera

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. F. Pollera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. F. Pollera. The network helps show where C. F. Pollera may publish in the future.

Co-authorship network of co-authors of C. F. Pollera

This figure shows the co-authorship network connecting the top 25 collaborators of C. F. Pollera. A scholar is included among the top collaborators of C. F. Pollera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. F. Pollera. C. F. Pollera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Cognetti, F., Enzo Maria Ruggeri, Alessandra Felici, et al.. (2008). Adjuvant chemotherapy (AC) with cisplatin + gemcitabine (CG) versus chemotherapy (CT) at relapse (CR) in patients (pts) with muscle-invasive bladder cancer (MIBC) submitted to radical cystectomy (RC). An Italian multicenter randomised phase III trial. Journal of Clinical Oncology. 26(15_suppl). 5023–5023. 21 indexed citations

Cazzaniga, Marina Elena, Giorgio Mustacchi, P. Pronzato, et al.. (2006). Switching from tamoxifen (TAM) to aromatase inhibitors (Als) in the adjuvant treatment of breast cancer (BC) patients (pts). Results from the NORA study. European Journal of Cancer Supplements. 4(2). 158–158. 1 indexed citations

Ruggeri, Enzo Maria, Diana Giannarelli, Emilio Bria, et al.. (2005). Adjuvant chemotherapy (AC) for muscle-invasive bladder cancer: A pooled analysis from phase III studies. Journal of Clinical Oncology. 23(16_suppl). 4664–4664. 1 indexed citations

Moscetti, Luca, et al.. (2005). Gemcitabine and Cisplatin in the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer: Impact of Comorbidities on Safety and Efficacy Outcome. Journal of Chemotherapy. 17(6). 685–692. 12 indexed citations

Pollera, C. F., Nicolò Merendino, Anna Maria Cianciulli, et al.. (2005). Preliminary cytogenetic and pharmacogenomic analysis of muscle-invasive transitional-cell carcinoma (TCC) of the bladder in patients (pts) enrolled in the Italian National Research Council (CNR) phase III randomized trial comparing adjuvant cisplatin-gemcitabine (PG) vs observation (OBS) after radical cystectomy. Journal of Clinical Oncology. 23(16_suppl). 4589–4589. 2 indexed citations

Zeuli, Massimo, Alain Gelibter, Teresa Gamucci, et al.. (2004). A feasibility study of gefitinib in association with capecitabine (CAP) and oxaliplatin (OXA) as first-line treatment in patients with advanced colorectal cancer (ACRC). Journal of Clinical Oncology. 22(14_suppl). 3748–3748. 14 indexed citations

Lorusso, Vito, C. F. Pollera, Mauro Antimi, et al.. (1998). A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. European Journal of Cancer. 34(8). 1208–1212. 242 indexed citations

Lena, M. De, Vito Lorusso, D. Amadori, et al.. (1995). 1147 Gemcitabine in resistant stage IV bladder cancer: A phase II study. European Journal of Cancer. 31. S240–S240. 2 indexed citations

Pollera, C. F., A. Ceribelli, M Crecco, & F. Calabresi. (1994). Weekly gemcitabine in advanced bladder cancer: A preliminary report from a phase I study. Annals of Oncology. 5(2). 182–184. 156 indexed citations

10.

Pollera, C. F., et al.. (1991). Alizapride Alone or Alizapride-Dexamethasone Compared with Metoclopramide-Dexamethasone in Patients at High Risk of Acute Emesis After Cisplatin. A Randomized Cross-over Study. Acta Oncologica. 30(6). 725–729. 1 indexed citations

11.

Nardi, Marco, F. Cognetti, C. F. Pollera, et al.. (1990). Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: a phase II study.. Journal of Clinical Oncology. 8(6). 1036–1041. 45 indexed citations

12.

Pollera, C. F., et al.. (1988). Very high-dose cisplatin-induced ototoxicity: a preliminary report on early and long-term effects. Cancer Chemotherapy and Pharmacology. 21(1). 61–4. 32 indexed citations

13.

Pollera, C. F., Mario Nardi, Paolo Marolla, & Paolo Carlini. (1987). A randomized trial comparing alizapride alone or with dexamethasone vs a metoclopramide-dexamethasone combination for emesis induced by moderate-dose cisplatin. Cancer Chemotherapy and Pharmacology. 19(4). 335–8. 3 indexed citations

14.

Pollera, C. F., et al.. (1987). Changes in serum iron levels following very high-dose cisplatin. Cancer Chemotherapy and Pharmacology. 19(3). 257–60. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact